Clinical Trials - May 11, 2022
Nykode Therapeutics announces positive interim trial results
Nykode Therapeutics has announced positive interim results from its Phase 2 VB C-02 trial of VB10.16, its wholly-owned therapeutic cancer vaccine, in combination with the PD-L1 inhibitor atezolizumab in patients with HPV16-positive advanced cervical cancer. Interim results from 39 patients with a median follow up of 6 months show an ORR of 21% – including […]
In a new job - February 2, 2022
He is the new Chairman at Nykode Therapeutics
Martin Nicklasson has been elected new chairman of Nykode Therapeutics as the company enters a new stage of internationalization. “I am delighted to join Nykode Therapeutics as new chairman. I am extremely impressed by the company’s technology platform and R&D pipeline, as well as the company’s outstanding achievements, including closing three landmark collaboration agreements over […]
COVID-19 - January 19, 2022
First subject dosed with Nykode’s vaccine candidate
Nykode Therapeutics has announced that the first subject has been dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate in its VB-D-01 Phase 1/2 trial. The T cell specific vaccine is designed to prime T cells, potentially generating a broad immune response against current and future variants. The VB-D-01 trial is a two-arm, open […]
Agreement - November 23, 2021
Vaccibody becomes Nykode and enters agreement worth 900 MUSD
The new name and identity signifies a new phase of growth for the company and the agreement with US-based Regeneron is worth up to 900 million USD. The multi-target license and collaboration agreement with Regeneron includes five distinct programs, three within cancer and two within infectious diseases. Each of these may include several vaccine candidates, […]
